Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Liabilities and Shareholders Equity (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Liabilities and Shareholders Equity for 11 consecutive years, with $19.1 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 13.4% to $19.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $72.6 million through Dec 2025, up 23.62% year-over-year, with the annual reading at $19.1 million for FY2025, 13.4% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $19.1 million at Marker Therapeutics, down from $21.7 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $88.4 million in Q1 2021, with the low at $10.9 million in Q3 2024.
  • Average Liabilities and Shareholders Equity over 5 years is $35.5 million, with a median of $22.0 million recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity soared 106.04% in 2021, then plummeted 58.04% in 2023.
  • Over 5 years, Liabilities and Shareholders Equity stood at $68.1 million in 2021, then tumbled by 49.48% to $34.4 million in 2022, then tumbled by 50.24% to $17.1 million in 2023, then rose by 28.58% to $22.0 million in 2024, then fell by 13.4% to $19.1 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $19.1 million, $21.7 million, and $14.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.